Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||triple-receptor negative breast cancer||not applicable||Alisertib + Docetaxel||Preclinical - Pdx & cell culture||Actionable||In a preclinical study, Alisertib (MLN8237) showed additive and synergistic antitumor activity with Taxotere (docetaxel) in primary tumor and cell line xenograft models of triple-negative breast cancer, resulting in tumor regression (PMID: 24980948).||24980948|